Karus Therapeutics, a UK-based developer of medicines for the treatment of inflammatory disease and cancer, has raised $7.6m in the first tranche of its series B round from a consortium including Denmark-based drugs company Novo.
Venture capital firms SV Life Sciences, New Leaf Ventures and International Biotechnology Trust also invested.